A prospective, multicentric study analysing efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies and chemotherapy in metastatic colorectal carcinoma (mCRC) patients
Latest Information Update: 17 Nov 2021
Price :
$35 *
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Epidermal growth factor inhibitors; Proto-oncogene protein b-raf inhibitors
- Indications Colorectal cancer
- Focus Therapeutic Use
- 17 Nov 2021 New trial record
- 21 Sep 2021 Primary endpoint has not been met. (overall survival), as per Results presented at the 46th European Society for Medical Oncology Congress
- 21 Sep 2021 Primary endpoint has not been met. (progression free survival),as per Results presented at the 46th European Society for Medical Oncology Congress